Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.
Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.
复制标题
米卡芬净在婴儿中的安全性、有效性和暴露反应：已建立的药代动力学模型在电子健康记录中的应用。
DOI：
10.1097/inf.0000000000002045
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Greenberg,RachelG
中科院分区：
文献类型：
--
作者：
Rivera-Chaparro,NazarioD;Ericson,Jessica;Wu,Huali;Smith,PBrian;Clark,ReeseH;BenjaminJr,DanielK;Cohen-Wolkowiez,Michael;Greenberg,RachelG
Micafungin在美国用于治疗新生儿侵袭性念珠菌病。我们使用一个已建立的药代动力学模型来确定39名住院婴儿46个疗程的米卡芬净暴露。在这个小的婴儿队列中，米卡芬净暴露与肝毒性、死亡或微生物清除失败的实验室标志物无关。
Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.